Regeneron Pharmaceuticals (BMV:REGN *) - Hisse Senedi Fiyatı, Haberler ve Analizler

REGN * Stoklara Genel Bakış

Regeneron Pharmaceuticals, Inc. dünya çapında çeşitli hastalıkların tedavisi için ilaçlar keşfetmekte, icat etmekte, geliştirmekte, üretmekte ve ticarileştirmektedir. Daha fazla detay

REGN * temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	5/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 55.9% daha düşük bir oranda işlem görüyor

Kazançlar geçen yıl 16.6% oranında arttı

Analistler hisse senedi fiyatının 44.8% oranında artacağı konusunda hemfikir

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

Regeneron Pharmaceuticals, Inc. Rakipler

CSL

ASX:CSL

AU$131.4b

Amgen

NasdaqGS:AMGN

US$150.5b

Biogen

NasdaqGS:BIIB

US$22.6b

AbbVie

NYSE:ABBV

US$294.4b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Regeneron Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$14,937.40
52 Haftanın En Yüksek Seviyesi	US$23,707.11
52 Haftanın En Düşük Seviyesi	US$13,696.61
Beta	0.14
11 Aylık Değişim	-24.17%
3 Aylık Değişim	-35.08%
1 Yıllık Değişim	8.23%
33 Yıllık Değişim	9.15%
5 Yıllık Değişim	105.68%
Halka arzdan bu yana değişim	64.58%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	REGN *	MX Biotechs	MX Pazar
7D	-12.0%	0%	0%
1Y	8.2%	0%	0%

Getiri vs. Endüstri: REGN * geçen yıl boyunca % 8 oranında getiri sağlayan MX Biotechs sektörüyle eşleşti.

Getiri vs Piyasa: REGN * geçen yıl % -3.7 oranında getiri sağlayan MX Piyasasını aştı.

Fiyat Oynaklığı

Is REGN *'s price volatile compared to industry and market?
REGN * volatility
REGN * Average Weekly Movement	6.7%
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

İstikrarlı Hisse Senedi Fiyatı: REGN * hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: REGN * 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1988	14,165	Leonard Schleifer	www.regeneron.com

Regeneron Pharmaceuticals, Inc. dünya çapında çeşitli hastalıkların tedavisi için ilaçlar keşfeder, icat eder, geliştirir, üretir ve ticarileştirir. Şirketin ürünleri arasında yaşlılığa bağlı makula dejenerasyonu ve diyabetik makula ödemini tedavi etmek için EYLEA enjeksiyonu; miyopik koroidal neovaskülarizasyon; diyabetik retinopati; neovasküler glokom; ve prematüre retinopatisi bulunmaktadır. Ayrıca yetişkinlerde ve pediatride atopik dermatit ve astımı tedavi etmek için Dupixent enjeksiyonu; metastatik veya lokal olarak ilerlemiş kutanöz skuamöz hücreli karsinomu tedavi etmek için Libtayo enjeksiyonu; yetişkinlerde heterozigot ailesel hiperkolesterolemi veya klinik aterosklerotik kardiyovasküler hastalık için Praluent enjeksiyonu; covid-19 için REGEN-COV ve yetişkinlerde romatoid artrit tedavisi için Kevzara solüsyonu sunmaktadır.

Regeneron Pharmaceuticals, Inc. Temel Bilgiler Özeti

Regeneron Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
REGN * temel i̇stati̇sti̇kler
Piyasa değeri	Mex$1.61t
Kazançlar(TTM)	Mex$93.64b
Gelir(TTM)	Mex$278.56b

17.2x

F/K Oranı

5.8x

P/S Oranı

REGN * aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
REGN * gelir tablosu (TTM)
Gelir	US$13.85b
Gelir Maliyeti	US$6.82b
Brüt Kâr	US$7.03b
Diğer Giderler	US$2.37b
Kazançlar	US$4.65b

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	43.26
Brüt Marj	50.75%
Net Kâr Marjı	33.61%
Borç/Özkaynak Oranı	6.8%

REGN * uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

REGN * Stoklara Genel Bakış

Ödüller

Risk Analizi

Regeneron Pharmaceuticals, Inc. Rakipler

ASX:CSL

AU$131.4b

NasdaqGS:AMGN

US$150.5b

NasdaqGS:BIIB

US$22.6b

NYSE:ABBV

US$294.4b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Senior VP of Finance & CFO recently sold Mex$124m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Insider recently sold Mex$108m worth of stock

Second quarter 2024 earnings released: EPS: US$13.25 (vs US$9.05 in 2Q 2023)

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

New minor risk - Shareholder dilution

First quarter 2024 earnings released: EPS: US$6.70 (vs US$7.64 in 1Q 2023)

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Executive VP recently sold Mex$17m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Insider recently sold Mex$168m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022)

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Regeneron Pharmaceuticals, Inc. Temel Bilgiler Özeti

17.2x

5.8x

Kazanç ve Gelir